Fulfilling its commitment, Serum Institute of India has produced over 10 crore doses of its COVID-19 vaccine Covishield in June so far as India ramps up the pace of its vaccination drive in the face of a possible third wave of the viral infection. India’s COVID-19
Domestic vaccine major Serum Institute of India is seeking indemnity from liability for its COVID vaccines, saying that the rules should be same for all the companies, according to sources. The development comes after requests for indemnity and exemption from bridging trials have been made
The World Health Organisation (WHO) said on Tuesday that it has approved China’s second COVID-19 vaccine ‘Sinovac’ for emergency use listing. “WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for
Serum Institute of India (SII) has informed the government that it will be able to manufacture and supply nine to 10 crore doses of Covishield in June, official sources said on Sunday amid complaint by states about the shortage of anti-coronavirus vaccine jabs. In a recent
Due to the unprecedented COVID-19 crisis in India, the global supply of COVAX has been badly hit, so much so that there are many parts of the world where one shot has been dispensed to health workers or frontline workers and the second shot has
